Skip to content
2000
image of Strategies for Screening and Managing Inflammatory Bowel Disease During Pregnancy

Abstract

Pregnancy is a critical phase of life for women; there are several hormonal changes during this period. Pregnant women, throughout their gestation, may be greatly impacted by disease conditions such as hypertension and diabetes mellitus. Inflammatory Bowel Disease (IBD) is a chronic condition involving inflammation of the gastrointestinal (GI) tract. Comprehending the connection between IBD and pregnancy is essential due to its effects on the pregestational, gestational, and postpartum phases. Pregnancy-related inflammatory bowel disease activity must be tracked using several techniques. The usefulness and reliability of small intestine ultrasound (IUS) as a trustworthy and noninvasive diagnostic tool are reviewed in this article. The increasing popularity of IUS requires skilled personnel for its effective use due to its technique-sensitive nature. In addition, this review provides an overview of the most recent data about the efficacy and safety of IBD treatments for expectant mothers to provide medical professionals with up-to-date clinical recommendations.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855394477250924234245
2025-10-17
2025-12-28

  • From This Site

    /content/journals/cdth/10.2174/0115748855394477250924234245
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Coward S. Clement F. Benchimol E.I. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019 156 5 1345 1353.e4 10.1053/j.gastro.2019.01.002 30639677
    [Google Scholar]
  2. Shivashankar R. Tremaine W.J. Harmsen W.S. Loftus E.V. Incidence and prevalence of crohn’s disease and ulcerative colitis in olmsted county, minnesota from 1970 through 2010. Clin. Gastroenterol. Hepatol. 2017 15 6 857 863 10.1016/j.cgh.2016.10.039 27856364
    [Google Scholar]
  3. Selinger C.P. Eaden J. Selby W. Patients’ knowledge of pregnancy‐related issues in inflammatory bowel disease and validation of a novel assessment tool (‘ CCPKnow ’). Aliment. Pharmacol. Ther. 2012 36 1 57 63 10.1111/j.1365‑2036.2012.05130.x 22568682
    [Google Scholar]
  4. Mountifield R. Bampton P. Prosser R. Muller K. Andrews J.M. Fear and fertility in inflammatory bowel disease: A mismatch of perception and reality affects family planning decisions. Inflamm. Bowel Dis. 2009 15 5 720 725 10.1002/ibd.20839 19067431
    [Google Scholar]
  5. De Dombal F.T. Watts J.M. Watkinson G. Goligher J.C. Ulcerative colitis and pregnancy. Lancet 1965 2 7413 599 602 10.1016/s0140‑6736(65)90513‑1
    [Google Scholar]
  6. Olsen K.Ø. Juul S. Berndtsson I. Öresland T. Laurberg S. Ulcerative colitis: Female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002 122 1 15 19 10.1053/gast.2002.30345 11781275
    [Google Scholar]
  7. Korelitz B.I. Inflammatory bowel disease and pregnancy. Gastroenterol. Clin. North Am. 1998 27 1 213 224 10.1016/S0889‑8553(05)70354‑X 9546091
    [Google Scholar]
  8. Hudson M. Flett G. Sinclair T.S. Brunt P.W. Templeton A. Mowat N.A.G. Fertility and pregnancy in inflammatory bowel disease. Int. J. Gynaecol. Obstet. 1997 58 2 229 237 10.1016/S0020‑7292(97)00088‑X 9252260
    [Google Scholar]
  9. Waljee A. Waljee J. Morris A.M. Higgins P.D.R. Threefold increased risk of infertility: A meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006 55 11 1575 1580 10.1136/gut.2005.090316 16772310
    [Google Scholar]
  10. Friedman S. Nielsen J. Nøhr E.A. Jølving L.R. Nørgård B.M. Comparison of time to pregnancy in women with and without inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2020 18 7 1537 1544.e1 10.1016/j.cgh.2019.08.031 31446182
    [Google Scholar]
  11. Oresland T. Palmblad S. Ellström M. Berndtsson I. Crona N. Hultén L. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int. J. Colorectal Dis. 1994 9 2 77 81 10.1007/BF00699417 8064194
    [Google Scholar]
  12. Brondfield M.N. Mahadevan U. Inflammatory bowel disease in pregnancy and breastfeeding. Nat. Rev. Gastroenterol. Hepatol. 2023 20 8 504 523 10.1038/s41575‑023‑00758‑3 37002407
    [Google Scholar]
  13. Bartels S.A.L. D’Hoore A. Cuesta M.A. Bensdorp A.J. Lucas C. Bemelman W.A. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: A cross-sectional study. Ann. Surg. 2012 256 6 1045 1048 10.1097/SLA.0b013e318250caa9 22609840
    [Google Scholar]
  14. Beyer-Berjot L. Maggiori L. Birnbaum D. Lefevre J.H. Berdah S. Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: A 2-center study. Ann. Surg. 2013 258 2 275 282 10.1097/SLA.0b013e3182813741 23360923
    [Google Scholar]
  15. Pavlov O. Selutin A. Pavlova O. Selkov S. Macrophages are a source of IL‐17 in the human placenta. Am. J. Reprod. Immunol. 2018 80 4 e13016 10.1111/aji.13016 29956865
    [Google Scholar]
  16. Padhan R.K. Kedia S. Garg S.K. Long-term disease course and pregnancy outcomes in women with inflammatory bowel disease: An indian cohort study. Dig. Dis. Sci. 2017 62 8 2054 2062 10.1007/s10620‑016‑4353‑5 27785711
    [Google Scholar]
  17. Kammerlander H. Nielsen J. Kjeldsen J. Knudsen T. Friedman S. Nørgård B. The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease. Inflamm. Bowel Dis. 2017 23 6 1011 1018 10.1097/MIB.0000000000001102 28346274
    [Google Scholar]
  18. Ban L. Tata L.J. Humes D.J. Fiaschi L. Card T. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: A United Kingdom population‐based cohort study. Aliment. Pharmacol. Ther. 2015 42 7 855 866 10.1111/apt.13354 26250873
    [Google Scholar]
  19. Zhao Y. Chen B. He Y. Risk factors associated with impaired ovarian reserve in young women of reproductive age with crohn’s disease. Intest. Res. 2020 18 2 200 209 10.5217/ir.2019.00103 32224833
    [Google Scholar]
  20. Bengtson M.B. Aamodt G. Mahadevan U. Vatn M.H. Inadequate gestational weight gain, the hidden link between maternal ibd and adverse pregnancy outcomes. Inflamm. Bowel Dis. 2017 23 7 1225 1233 10.1097/MIB.0000000000001123 28452861
    [Google Scholar]
  21. Bengtson M.B. Martin C.F. Aamodt G. Vatn M.H. Mahadevan U. Inadequate gestational weight gain predicts adverse pregnancy outcomes in mothers with inflammatory bowel disease: results from a prospective us pregnancy cohort. Dig. Dis. Sci. 2017 62 8 2063 2069 10.1007/s10620‑017‑4547‑5 28332106
    [Google Scholar]
  22. de Lima A. Zelinkova Z. Mulders A.G.M.G.J. van der Woude C.J. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin. Gastroenterol. Hepatol. 2016 14 9 1285 1292.e1 10.1016/j.cgh.2016.03.018 27001269
    [Google Scholar]
  23. Nguyen G.C. Seow C.H. Maxwell C. Huang V. Leung Y. Jones J. Canadian association of gastroenterology. The toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016 150 3 734 757.e1 10.1053/j.gastro.2015.12.003 26688268
    [Google Scholar]
  24. D’Haens G. Sandborn W.J. Feagan B.G. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007 132 2 763 786 10.1053/j.gastro.2006.12.038 17258735
    [Google Scholar]
  25. Sandborn W.J. Feagan B.G. Hanauer S.B. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002 122 2 512 530 10.1053/gast.2002.31072 11832465
    [Google Scholar]
  26. Sandborn W.J. Panés J. Zhang H. Yu D. Niezychowski W. Su C. Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a Phase 2 Trial. Gastroenterology 2016 150 1 96 102 10.1053/j.gastro.2015.09.001 26376350
    [Google Scholar]
  27. Kammerlander H. Nielsen J. Kjeldsen J. Fecal calprotectin during pregnancy in women with moderate-severe inflammatory bowel disease. Inflamm. Bowel Dis. 2018 24 4 839 848 10.1093/ibd/izx055 29506137
    [Google Scholar]
  28. Friedman S. McElrath T.F. Wolf J.L. Management of fertility and pregnancy in women with inflammatory bowel disease: A practical guide. Inflamm. Bowel Dis. 2013 19 13 2937 2948 10.1097/MIB.0b013e3182a0ea6f 23945187
    [Google Scholar]
  29. Bell S.J. Flanagan E.K. Updates in the management of inflammatory bowel disease during pregnancy. Med. J. Aust. 2019 210 6 276 280 10.5694/mja2.50062 30905081
    [Google Scholar]
  30. Klajnbard A Szecsi PB Colov NP Laboratory reference in-tervals during pregnancy, delivery and the early postpartum period cclm 2010 48 2 237 48 10.1515/CCLM.2010.033 19943809
    [Google Scholar]
  31. Julsgaard M. Hvas C.L. Gearry R.B. Fecal calprotectin is not affected by pregnancy. Inflamm. Bowel Dis. 2017 23 7 1240 1246 10.1097/MIB.0000000000001136 28498159
    [Google Scholar]
  32. Rottenstreich A. Mishael T. Granovsky S.G. Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. Eur. J. Intern. Med. 2020 77 105 110 10.1016/j.ejim.2020.03.015 32197833
    [Google Scholar]
  33. Selinger C.P. Nelson-Piercy C. Fraser A. IBD in pregnancy: Recent advances, practical management. Frontline Gastroenterol. 2021 12 3 214 224 10.1136/flgastro‑2019‑101371 33912333
    [Google Scholar]
  34. Tandon P. Leung K. Yusuf A. Huang V.W. Noninvasive methods for assessing inflammatory bowel disease activity in pregnancy. J. Clin. Gastroenterol. 2019 53 8 574 581 10.1097/MCG.0000000000001244 31306343
    [Google Scholar]
  35. Bal J Foshaug R Ambrosio L Kroeker K Dieleman L Halloran B. P247. C-reactive protein is elevated with clinical disease activ-ity during pregnancy in women with Inflammatory Bowel Disease J Crohn’s Colitis 2015 9 S199 200.(Suppl. 1) 10.1093/ecco‑jcc/jju027.364
    [Google Scholar]
  36. Schulze H. Esters P. Dignass A. Review article: The management of Crohn’s disease and ulcerative colitis during pregnancy and lactation. Aliment. Pharmacol. Ther. 2014 40 9 991 1008 10.1111/apt.12949 25200000
    [Google Scholar]
  37. Guerrero Vinsard D. Karagozian R. Wakefield D.B. Kane S.V. Maternal outcomes and pregnancy-related complications among hospitalized women with inflammatory bowel disease: report from the national inpatient sample. Dig. Dis. Sci. 2022 67 9 4295 4302 10.1007/s10620‑021‑07210‑z 34406586
    [Google Scholar]
  38. Choden T. Mandaliya R. Charabaty A. Mattar M.C. Monitoring inflammatory bowel disease during pregnancy: Current literature and future challenges. World J. Gastrointest. Pharmacol. Ther. 2018 9 1 1 7 10.4292/wjgpt.v9.i1.1 29430322
    [Google Scholar]
  39. Siddiqui I. Majid H. Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J. Gastrointest. Pharmacol. Ther. 2017 8 1 39 46 10.4292/wjgpt.v8.i1.39 28217373
    [Google Scholar]
  40. Gisbert J.P. McNicholl A.G. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis. 2009 41 1 56 66 10.1016/j.dld.2008.05.008 18602356
    [Google Scholar]
  41. Sipponen T. Kärkkäinen P. Savilahti E. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment. Pharmacol. Ther. 2008 28 10 1221 1229 10.1111/j.1365‑2036.2008.03835.x 18752630
    [Google Scholar]
  42. Schoepfer A.M. Beglinger C. Straumann A. Trummler M. Renzulli P. Seibold F. Ulcerative colitis. Inflamm. Bowel Dis. 2009 15 12 1851 1858 10.1002/ibd.20986 19462421
    [Google Scholar]
  43. Kostas A. Siakavellas S.I. Kosmidis C. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J. Gastroenterol. 2017 23 41 7387 7396 10.3748/wjg.v23.i41.7387 29151692
    [Google Scholar]
  44. Tibble J. Teahon K. Thjodleifsson B. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000 47 4 506 513 10.1136/gut.47.4.506 10986210
    [Google Scholar]
  45. Schoepfer A.M. Trummler M. Seeholzer P. Seibold-Schmid B. Seibold F. Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis. 2008 14 1 32 39 10.1002/ibd.20275 17924558
    [Google Scholar]
  46. Colombel J.F. Panaccione R. Bossuyt P. Effect of tight control management on Crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet 2017 390 10114 2779 2789 10.1016/S0140‑6736(17)32641‑7 29096949
    [Google Scholar]
  47. Huang V. Bal J. Foshaug R.R. Su1255 fecal calprotectin is elevated with clinical disease activity during pregnancy in women with inflammatory bowel disease. Gastroenterology 2015 148 4 S-452 10.1016/S0016‑5085(15)31526‑2
    [Google Scholar]
  48. Barré A. Tarassishin L. Eisele C. Su1792 - Fecal lactoferrin is a reliable ibd biomarker during pregnancy. Gastroenterology 2018 154 6 S-585 S-586 10.1016/S0016‑5085(18)32138‑3
    [Google Scholar]
  49. Kanis S.L. de Lima A. van der Ent C. van der Woude C.J. Sa1941 Anti-TNF Cord levels are significantly higher after ifx exposure during pregnancy compared to ada exposure. Gastroenterology 2016 150 4 S410 10.1016/S0016‑5085(16)31429‑9
    [Google Scholar]
  50. Kaitha S. Bashir M. Ali T. Iron deficiency anemia in inflammatory bowel disease. World J. Gastrointest. Pathophysiol. 2015 6 3 62 72 10.4291/wjgp.v6.i3.62 26301120
    [Google Scholar]
  51. Bröms G. Granath F. Linder M. Stephansson O. Elmberg M. Kieler H. Complications from inflammatory bowel disease during pregnancy and delivery. Clin. Gastroenterol. Hepatol. 2012 10 11 1246 1252 10.1016/j.cgh.2012.08.018 22922307
    [Google Scholar]
  52. Mahadevan U. Robinson C. Bernasko N. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the american gastroenterological association ibd parenthood project working group. Gastroenterology 2019 156 5 1508 1524 10.1053/j.gastro.2018.12.022 30658060
    [Google Scholar]
  53. De Voogd F. Joshi H. Van Wassenaer E. Bots S. D’Haens G. Gecse K. Intestinal ultrasound to evaluate treatment response during pregnancy in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2022 28 7 1045 1052 10.1093/ibd/izab216 34525186
    [Google Scholar]
  54. Ko M.S. Rudrapatna V.A. Avila P. Mahadevan U. Safety of flexible sigmoidoscopy in pregnant patients with known or suspected inflammatory bowel disease. Dig. Dis. Sci. 2020 65 10 2979 2985 10.1007/s10620‑020‑06122‑8 32034603
    [Google Scholar]
  55. Chan Y.M. Ngai S.W. Lao T.T. Colon cancer in pregnancy. A case report. J. Reprod. Med. 1999 44 8 733 736 10483546
    [Google Scholar]
  56. Huang W.S. Lin P.Y. Wang J.Y. Chin C.C. Hsieh C.C. Urgent colectomy and caesarean section of a pregnant familial adenomatous polyposis: A case report. Int. J. Colorectal Dis. 2007 22 7 847 848 10.1007/s00384‑006‑0087‑8 16479367
    [Google Scholar]
  57. Gibbs J. Newson T. Williams J. Davidson D.C. Naloxone hazard in infant of opioid abuser. Lancet 1989 334 8655 159 160 10.1016/S0140‑6736(89)90214‑6 2567922
    [Google Scholar]
  58. Nancey S. Fumery M. Faure M. Use of imaging modalities for decision-making in inflammatory bowel disease. Therap. Adv. Gastroenterol. 2023 16 17562848231151293 10.1177/17562848231151293 36777362
    [Google Scholar]
  59. Lowe S. Diagnostic imaging in pregnancy: Making informed decisions. Obstet. Med. 2019 12 3 116 122 10.1177/1753495X19838658 31523267
    [Google Scholar]
  60. Frangione B. Hinton P. Villeneuve P.J. Low-dose ionizing radiation and adverse birth outcomes: A systematic review and meta-analysis. Int. Arch. Occup. Environ. Health 2023 96 1 77 92 10.1007/s00420‑022‑01911‑2 35913560
    [Google Scholar]
  61. Brent R.L. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: Counseling the pregnant and nonpregnant patient about these risks. Semin. Oncol. 1989 16 5 347 368 10.1097/00003081‑198306000‑00030 2678486
    [Google Scholar]
  62. Hufton A.P. Radiation dose to the fetus in obstetric radiography. Br. J. Radiol. 1979 52 621 735 740 10.1259/0007‑1285‑52‑621‑735 476388
    [Google Scholar]
  63. Flanagan E. Bell S. Abdominal Imaging in pregnancy (maternal and foetal risks). Best Pract. Res. Clin. Gastroenterol. 2020 44-45 101664 10.1016/j.bpg.2019.101664 32359678
    [Google Scholar]
  64. Nicolaides K.H. Guidelines for diagnostic imaging during pregnancy and lactation—acog committee opinion. Am CollObstet Gynecol 2017 701 1 4 10.1097/AOG.0000000000002355
    [Google Scholar]
  65. Mustafa B.F. Samaan M. Langmead L. Khasraw M. Small bowel video capsule endoscopy: An overview. Expert Rev. Gastroenterol. Hepatol. 2013 7 4 323 329 10.1586/egh.13.20 23639090
    [Google Scholar]
  66. Hogan R.B. Ahmad N. Hogan R.B. Video capsule endoscopy detection of jejunal carcinoid in life-threatening hemorrhage, first trimester pregnancy. Gastrointest. Endosc. 2007 66 1 205 207 10.1016/j.gie.2006.11.021 17521645
    [Google Scholar]
  67. Spinelli A. Bonovas S. Burisch J. ECCO guidelines on therapeutics in ulcerative colitis: Surgical treatment. J. Crohn’s Colitis 2022 16 2 179 189 10.1093/ecco‑jcc/jjab177 34635910
    [Google Scholar]
  68. Shoenut J.P. Semelka R.C. Silverman R. Yaffe C.S. Micflikier A.B. MRI in the diagnosis of Crohn’s disease in two pregnant women. J. Clin. Gastroenterol. 1993 17 3 244 247 10.1097/00004836‑199310000‑00015 8228087
    [Google Scholar]
  69. Ray J.G. Vermeulen M.J. Bharatha A. Montanera W.J. Park A.L. Association between mri exposure during pregnancy and fetal and childhood outcomes. JAMA 2016 316 9 952 961 10.1001/jama.2016.12126 27599330
    [Google Scholar]
  70. Sinha R. Nwokolo C. Murphy P.D. Magnetic resonance imaging in Crohn’s disease. BMJ 2008 336 7638 273 276 10.1136/bmj.39456.527419.80 18245000
    [Google Scholar]
  71. Winter R. Nørgård B.M. Friedman S. Treatment of the pregnant patient with inflammatory bowel disease. Inflamm. Bowel Dis. 2016 22 3 733 744 10.1097/MIB.0000000000000625 26658216
    [Google Scholar]
  72. Flanagan E. Wright E.K. Begun J. Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography. J. Crohn’s Colitis 2020 14 10 1405 1412 10.1093/ecco‑jcc/jjaa082 32343768
    [Google Scholar]
  73. van der Woude C.J. Ardizzone S. Bengtson M.B. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J. Crohn’s Colitis 2015 9 2 107 124 10.1093/ecco‑jcc/jju006 25602023
    [Google Scholar]
  74. Rahimi R. Nikfar S. Rezaie A. Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: A meta-analysis. Reprod. Toxicol. 2008 25 2 271 275 10.1016/j.reprotox.2007.11.010 18242053
    [Google Scholar]
  75. Nørgård B. Fonager K. Pedersen L. Jacobsen B.A. Sørensen H.T. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: A Danish cohort study. Gut 2003 52 2 243 247 10.1136/gut.52.2.243 12524407
    [Google Scholar]
  76. Newman N.M. Correy J.F. Possible teratogenicity of sulphasalazine. Med. J. Aust. 1983 1 11 528 529 10.5694/j.1326‑5377.1983.tb136199.x 6133211
    [Google Scholar]
  77. Nørgård B. Hundborg H.H. Jacobsen B.A. Nielsen G.L. Fonager K. Disease activity in pregnant women with Crohn’s disease and birth outcomes: A regional Danish cohort study. Am. J. Gastroenterol. 2007 102 9 1947 1954 10.1111/j.1572‑0241.2007.01355.x 17573787
    [Google Scholar]
  78. Mogadam M. Dobbins W.O. Korelitz B.I. Ahmed S.W. Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981 80 1 72 76 10.1016/0016‑5085(81)90193‑1 6108894
    [Google Scholar]
  79. Czeizel A.E. Rockenbauer M. A population based case‐control teratologic study of oral metronidazole treatment during pregnancy. BJOG 1998 105 3 322 327 10.1111/j.1471‑0528.1998.tb10094.x 9532994
    [Google Scholar]
  80. Koss C.A. Baras D.C. Lane S.D. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob. Agents Chemother. 2012 56 9 4800 4805 10.1128/AAC.06477‑11 22751543
    [Google Scholar]
  81. Caro-Patón T. Carvajal A. Martín de Diego I. Martín-Arias L.H. Alvarez Requejo A. Pinilla E.R. Is metronidazole teratogenic? A meta‐analysis. Br. J. Clin. Pharmacol. 1997 44 2 179 182 10.1046/j.1365‑2125.1997.00660.x 9278206
    [Google Scholar]
  82. Burtin P. Taddio A. Ariburnu O. Einarson T.R. Koren G. Safety of metronidazole in pregnancy: A meta-analysis. Am. J. Obstet. Gynecol. 1995 172 2 525 529 10.1016/0002‑9378(95)90567‑7 7856680
    [Google Scholar]
  83. Linseman D. Hampton L.A. Branstetter D.G. Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam. Appl. Toxicol. 1995 28 1 59 64 10.1006/faat.1995.1146 8566484
    [Google Scholar]
  84. Niebyl J.R. Antibiotics and other anti-infective agents in pregnancy and lactation. Am. J. Perinatol. 2003 20 8 405 414 10.1055/s‑2003‑45391 14703588
    [Google Scholar]
  85. Bar-Oz B. Moretti M.E. Boskovic R. O’Brien L. Koren G. The safety of quinolones—A meta-analysis of pregnancy outcomes. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009 143 2 75 78 10.1016/j.ejogrb.2008.12.007 19181435
    [Google Scholar]
  86. Park-Wyllie L. Mazzotta P. Pastuszak A. Birth defects after maternal exposure to corticosteroids: Prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000 62 6 385 392 10.1002/1096‑9926(200012)62:6<385:AID‑TERA5>3.0.CO;2‑Z 11091360
    [Google Scholar]
  87. Carmichael S.L. Shaw G.M. Ma C. Werler M.M. Rasmussen S.A. Lammer E.J. Maternal corticosteroid use and orofacial clefts. Am. J. Obstet. Gynecol. 2007 197 6 585.e1 585.e7 10.1016/j.ajog.2007.05.046
    [Google Scholar]
  88. Gur C. Diav-Citrin O. Shechtman S. Arnon J. Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: A prospective controlled study. Reprod. Toxicol. 2004 18 1 93 101 10.1016/j.reprotox.2003.10.007 15013068
    [Google Scholar]
  89. Hviid A. Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011 183 7 796 804 10.1503/cmaj.101063 21482652
    [Google Scholar]
  90. Beaulieu D.B. Ananthakrishnan A.N. Issa M. Budesonide induction and maintenance therapy for Crohnʼs disease during pregnancy. Inflamm. Bowel Dis. 2009 15 1 25 28 10.1002/ibd.20640 18680195
    [Google Scholar]
  91. Cleary B.J. Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res. A Clin. Mol. Teratol. 2009 85 7 647 654 10.1002/bdra.20583 19343728
    [Google Scholar]
  92. Nørgård B. Pedersen L. Fonager K. Rasmussen S.N. Sørensen H.T. Azathioprine, mercaptopurine and birth outcome: A population‐based cohort study. Aliment. Pharmacol. Ther. 2003 17 6 827 834 10.1046/j.1365‑2036.2003.01537.x 12641505
    [Google Scholar]
  93. Francella A. Dyan A. Bodian C. Rubin P. Chapman M. Present D.H. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study. Gastroenterology 2003 124 1 9 17 10.1053/gast.2003.50014 12512024
    [Google Scholar]
  94. Moskovitz D.N. Bodian C. Chapman M.L. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am. J. Gastroenterol. 2004 99 4 656 661 10.1111/j.1572‑0241.2004.04140.x 15089898
    [Google Scholar]
  95. Casanova M.J. Chaparro M. Domènech E. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am. J. Gastroenterol. 2013 108 3 433 440 10.1038/ajg.2012.430 23318480
    [Google Scholar]
  96. Hutson J.R. Matlow J.N. Moretti M.E. Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J. Obstet. Gynaecol. 2013 33 1 1 8 10.3109/01443615.2012.716106 23259868
    [Google Scholar]
  97. Connell W.R. Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. Inflamm. Bowel Dis. 1996 2 1 33 47 10.1097/00054725‑199603000‑00006 23282454
    [Google Scholar]
  98. Beghin D. Cournot M.P. Vauzelle C. Elefant E. Paternal exposure to methotrexate and pregnancy outcomes. J. Rheumatol. 2011 38 4 628 632 10.3899/jrheum.100600 21239747
    [Google Scholar]
  99. Simister N. Placental transport of immunoglobulin G. Vaccine 2003 21 24 3365 3369 10.1016/S0264‑410X(03)00334‑7 12850341
    [Google Scholar]
  100. Julsgaard M. Christensen L.A. Gibson P.R. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016 151 1 110 119 10.1053/j.gastro.2016.04.002 27063728
    [Google Scholar]
  101. Mahadevan U. Wolf D.C. Dubinsky M. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2013 11 3 286 292 10.1016/j.cgh.2012.11.011 23200982
    [Google Scholar]
  102. Lichtenstein G.R. Feagan B.G. Cohen R.D. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006 4 5 621 630 10.1016/j.cgh.2006.03.002 16678077
    [Google Scholar]
  103. Katz J.A. Antoni C. Keenan G.F. Smith D.E. Jacobs S.J. Lichtenstein G.R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am. J. Gastroenterol. 2004 99 12 2385 2392 10.1111/j.1572‑0241.2004.30186.x 15571587
    [Google Scholar]
  104. Schnitzler F. Fidder H. Ferrante M. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm. Bowel Dis. 2011 17 9 1846 1854 10.1002/ibd.21583 21830263
    [Google Scholar]
  105. Mahadevan U Martin CF Sandler RS 1000 patient prospec-tive registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy Gastroenterology 2012 142 5 S 149.(Suppl. 1) 10.1016/S0016‑5085(12)60561‑7
    [Google Scholar]
  106. Zelinkova Z. van der Ent C. Bruin K.F. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin. Gastroenterol. Hepatol. 2013 11 3 318 321 10.1016/j.cgh.2012.10.024 23103819
    [Google Scholar]
  107. Lau A. Cleark M. Harriosn D. Geldhof A. Nissinen R. Sanders M. Pregnancy outcomes in women exposed to golimumab. ACR/ARHP Annual Meeting. San Diego, CA, USA, 06 April 2013
    [Google Scholar]
  108. Cheent K. Nolan J. Shariq S. Kiho L. Pal A. Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s Disease. J. Crohn’s Colitis 2010 4 5 603 605 10.1016/j.crohns.2010.05.001 21122568
    [Google Scholar]
  109. de Lima A. Zelinkova Z. van der Ent C. Steegers E A P. van der Woude C.J. Tailored anti-TNF therapy during pregnancy in patients with IBD: Maternal and fetal safety. Gut 2016 65 8 1261 1268 10.1136/gutjnl‑2015‑309321 25966992
    [Google Scholar]
  110. Mahadevan U. Vermeire S. Lasch K. Vedolizumab exposure in pregnancy: Outcomes from clinical studies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2017 45 7 941 950 10.1111/apt.13960 28169436
    [Google Scholar]
  111. Rocha K. Piccinin M.C. Kalache L.F. Reichert-Faria A. Silva de Castro C.C. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology 2015 231 2 103 104 10.1159/000380880 25790947
    [Google Scholar]
  112. Al-jabri R. Wetwittayakhlang P. Lakatos P.L. Monitoring of inflammatory bowel disease in pregnancy: A review of the different modalities. J. Clin. Med. 2023 12 23 7343 10.3390/jcm12237343 38068395
    [Google Scholar]
  113. Pinder M. Lummis K. Selinger C.P. Managing inflammatory bowel disease in pregnancy: Current perspectives. Clin. Exp. Gastroenterol. 2016 9 325 335 10.2147/CEG.S96676 27789969
    [Google Scholar]
  114. STELARA®(ustekinumab) prescribing information. Horsham, PA Janssen Biotech 2020
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855394477250924234245
Loading
Strategies for Screening and Managing Inflammatory Bowel Disease During Pregnancy
Bentham Science Publishers ; https://doi.org/10.2174/0115748855394477250924234245
/content/journals/cdth/10.2174/0115748855394477250924234245
/content/journals/cdth/10.2174/0115748855394477250924234245
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: radiological imaging ; Inflammatory bowel disease ; corticosteroids ; amino salicylates ; pregnancy ; antibiotics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test